Ocumetics to Form Scientific Advisory Committee
Calgary, Alberta — January 9, 2026 — Leads & Copy — Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced its intention to form a Scientific Advisory Committee (SAC), replacing the current single Chief Medical Officer role.
The consulting agreement with Dr. Doyle Stulting, the Corporation’s current Chief Medical Officer, will terminate after a ninety-day transition period. As Ocumetics moves closer to completing its First-in-Human (FIH) study and prepares for a pivotal FDA clinical trial anticipated in 2027, it is evolving its medical and clinical leadership structure to align with its next phase of growth. The transition involves moving from a single CMO structure to a broader, multi-member Scientific Advisory Committee (SAC) structure. The new committee will provide more in-depth and diverse medical, clinical, and regulatory oversight as the company advances toward late-stage clinical development. The SAC is intended to be composed of internationally recognized experts in ophthalmology, medical research, and lens science. This will allow the Company to leverage broader expertise across multiple disciplines critical to a successful pivotal trial and commercialization pathway. Ocumetics will announce the members of the Scientific Advisory Committee in the coming months. The company remains focused on advancing its accommodating intraocular lens technology and executing its clinical and regulatory strategy. President and CEO of Ocumetics, Dean Burns, acknowledged Dr. Stulting’s contributions to Ocumetics’ development, including decades of clinical expertise, research insight, and leadership to the Company’s scientific and clinical programs. Burns thanked Dr. Stulting for his service and wished him continued success. Ocumetics Technology Corp. is a Canadian research and product development company focused on developing advanced vision correction solutions. It has developed an intraocular lens that fits within the natural lens compartment of the eye. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses. Ocumetics is currently in the first-in-human early feasibility study phase. Dave Burwell, Director of Investor Relations, can be contacted at dave.burwell@ocumetics.com or (403) 410-7907 for further information. Source: OcumeticsShare this story:
